(Q33411718)

English

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

James Chih-Hsin Yang

object named as

James Chih-Hsin Yang

12

0 references

object named as

Ann-Lii Cheng

13

0 references

5

object named as

Eunice L Kwak

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Sharad Ghamande

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Chia-Chi Lin

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Daniel C Cho

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Geoffrey I Shapiro

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael H Silverman

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yunlong Tseng

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Min-Wen Kuo

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Wendy B Mach

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Shu-Chi Hsu

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Teresa Coleman

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mohammad H Ghalib

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Imran Chuadhary

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sanjay Goel

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

24 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

445-451

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s10637-013-0044-7

0 references

Topoisomerase I inhibitors: camptothecins and beyond

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0044-7

21 January 2018

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0044-7

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0044-7

21 January 2018

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0044-7

21 January 2018

Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0044-7

21 January 2018

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24271274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24271274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/24271274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhancement of radiation-induced DNA damage and inhibition of its repair by a novel camptothecin analog

1 reference

https://pubmed.ncbi.nlm.nih.gov/24271274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-013-0044-7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33411718&oldid=2144489053"